| Literature DB >> 33994729 |
Arun Chaturvedi1, Vijay Kumar1, Sameer Gupta1.
Abstract
Gall bladder carcinoma (GBC) is a worldwide problem, with a higher incidence in areas of the world where cholelithiasis is common. As GBC is usually diagnosed in an advanced stage, the mortality is high. An understanding of the molecular pathways of carcinogenesis and the mutations involved in the development and progression of GBC could be useful in early diagnosis. Understanding molecular markers of prognosis as well as predictors of outcome could also potentially benefit patients undergoing treatment. New therapies targeting major molecular pathways and immunotherapy are exciting novel therapeutic options. This review focuses on the current understanding of the molecular oncology of GBC. © Indian Association of Surgical Oncology 2019.Entities:
Keywords: Biliary cancers; Gall bladder carcinoma; Immunotherapy; Molecular oncology; Mutations; Targeted therapy
Year: 2019 PMID: 33994729 PMCID: PMC8119519 DOI: 10.1007/s13193-019-01008-2
Source DB: PubMed Journal: Indian J Surg Oncol ISSN: 0975-7651